Healthcare provider profile · identity verified

Ayemyint Ma, MD

Internal Medicine · PLEASANTON, CA · NPI 1649322868

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	483	166
Amlodipine Besylate	Amlodipine Besylate	311	107
Losartan Potassium	Losartan Potassium	237	74
Atenolol	Atenolol	214	67
Metformin Hcl Er	Metformin Hcl	206	74
Levothyroxine Sodium	Levothyroxine Sodium	179	52
Lisinopril	Lisinopril	138	47
Alendronate Sodium	Alendronate Sodium	129	38
Omeprazole	Omeprazole	119	45
Albuterol Sulfate Hfa	Albuterol Sulfate	113	50
Simvastatin	Simvastatin	113	38
Famotidine	Famotidine	109	46
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	107	32
Hydrochlorothiazide	Hydrochlorothiazide	89	30
Metformin Hcl	Metformin Hcl	82	26
Glipizide	Glipizide	66	22
Gabapentin	Gabapentin	64	26
Metoprolol Tartrate	Metoprolol Tartrate	63	19
Lovastatin	Lovastatin	55	17
Metoprolol Succinate	Metoprolol Succinate	55	16
Allopurinol	Allopurinol	49	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	49	17
Fluticasone Propionate	Fluticasone Propionate	47	23
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	47	suppressed
Furosemide	Furosemide	46	18
Meloxicam	Meloxicam	45	19
Alvesco	Ciclesonide	44	17
Rosuvastatin Calcium	Rosuvastatin Calcium	43	13
Pantoprazole Sodium	Pantoprazole Sodium	41	13
Triamcinolone Acetonide	Triamcinolone Acetonide	41	28
Wixela Inhub	Fluticasone Propion/Salmeterol	40	suppressed
Jardiance	Empagliflozin	39	17
Lorazepam	Lorazepam	38	suppressed
Cefadroxil	Cefadroxil	35	31
Lidocaine	Lidocaine	34	18
Tramadol Hcl	Tramadol Hcl	34	16
Trazodone Hcl	Trazodone Hcl	33	17
Ibuprofen	Ibuprofen	31	15
Tamsulosin Hcl	Tamsulosin Hcl	31	11
Sertraline Hcl	Sertraline Hcl	29	suppressed
Duloxetine Hcl	Duloxetine Hcl	27	12
Fluocinonide	Fluocinonide	27	17
Terazosin Hcl	Terazosin Hcl	27	suppressed
Carvedilol	Carvedilol	26	suppressed
Potassium Chloride	Potassium Chloride	26	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	24	suppressed
Azithromycin	Azithromycin	24	22
Mupirocin	Mupirocin	23	21
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	22	22
Clopidogrel	Clopidogrel Bisulfate	22	suppressed
Hydralazine Hcl	Hydralazine Hcl	22	suppressed
Temazepam	Temazepam	22	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	22	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Buspirone Hcl	Buspirone Hcl	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	17	16
Humulin N	Insulin Nph Human Isophane	17	suppressed
Hydrocortisone	Hydrocortisone	17	14
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	17	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	15	14
Amoxicillin	Amoxicillin	14	suppressed
Naproxen	Naproxen	14	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	14	suppressed
Spiriva Respimat	Tiotropium Bromide	14	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	13	suppressed
Colchicine	Colchicine	13	suppressed
Digoxin	Digoxin	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Montelukast Sodium	Montelukast Sodium	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Pravastatin Sodium	Pravastatin Sodium	13	suppressed
Terbinafine Hcl	Terbinafine Hcl	13	suppressed
Ibandronate Sodium	Ibandronate Sodium	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Baclofen	Baclofen	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	11
Prednisone	Prednisone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error